Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m).
Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
As per the deal, Glenmark Pharma is selling the stake in the life sciences unit for Rs615 for each share.
Following the divestiture, Glenmark Pharma will own a 7.84% stake in GLS.
Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said: “We are pleased to announce this strategic transaction with Nirma, which marks a significant milestone in shaping an independent growth trajectory for GLS.
“This deal aligns with our strategic intent of moving up the value chain to become an innovative/brand-led organisation, with continuous focus on our core therapeutic areas of dermatology, respiratory and oncology.
“It also presents an opportunity for us to strengthen shareholder value through deleveraging and enhancing our overall return profile.”
The conclusion of the deal is subject to necessary closing conditions and approvals from shareholders and regulators.
Following the deal closing, GLS will work as an independent API company under Nirma.
Furthermore, Nirma will make a compulsory open offer to all GLS public shareholders.
Glenmark Pharma continues to maintain growth across all its crucial markets while focusing on return ratios, eventually generating value for the shareholders of the company.
Kotak Investment Banking served as the exclusive financial adviser for Glenmark Pharma and GLS.
S&R Associates and Trilegal were the legal advisers to Glenmark Pharma and GLS, respectively.
Source: pharmaceutical-technology.com
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
